eFFECTOR Therapeutics (EFTR) Issues Pipeline and Business Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. TMUS
9. SPY
10. SBUX

Go back to eFFECTOR Therapeutics (EFTR) Issues Pipeline and Business Updates

eFFECTOR Therapeutics Provides Pipeline and Business Updates

January 24, 2022 4:00 PM EST

Tomivosertib development strategy updated, including addition of a new cohort in Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) evaluating frontline maintenance in PD-L1 1% patient population, representing additional $5 billion U.S. market opportunity

First patients dosed in two additional Phase 2 expansion cohorts evaluating zotatifin in combination with sotorasib in KRAS G12C-mutant NSCLC and in combination with abemaciclib and fulvestrant in ER+/HER2- breast cancer

Company enters into investment agreement with Lincoln Park Capital for up to $50... More